Did the FDA find a link between Wegovy and suicidal thoughts?

No, the FDA's review of 91 trials found no evidence linking GLP-1 drugs like Wegovy to an increased risk of suicidal thoughts or behavior.

Which weight-loss drugs are affected by the FDA's warning removal?

The FDA requested label warning removals for GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy, Saxenda, and Eli Lilly's Zepbound.

What is the purpose of GLP-1 drugs according to the FDA?

GLP-1 receptor agonists were initially developed for type 2 diabetes and work by mimicking a gut hormone to suppress appetite.

Home / Health / FDA Clears Wegovy, Zepbound: No Suicidal Thoughts Link

FDA Clears Wegovy, Zepbound: No Suicidal Thoughts Link

13 Jan

•

Summary

FDA removes warnings about suicidal thoughts for GLP-1 drugs.
Wegovy, Zepbound, and Saxenda are among affected medications.
Review covered over 107,000 patients in 91 clinical trials.

The U.S. health regulator has directed drugmakers to remove warnings about potential suicidal thoughts from widely used GLP-1 weight-loss drugs. This guidance impacts medications such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, as well as Novo's Saxenda.

The U.S. Food and Drug Administration's request stems from a comprehensive review of clinical trial data. This analysis, involving 91 trials with over 107,000 participants, found no evidence linking GLP-1 receptor agonists to an increased risk of suicidal thoughts or behavior.

Originally developed for type 2 diabetes, GLP-1 drugs mimic a gut hormone to suppress appetite. The FDA's latest conclusion reinforces an earlier preliminary review, asserting that these drugs do not pose a greater psychiatric risk compared to placebos.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.